RBD-NVP

A candidate COVID-19 nanoparticle vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

RBD-NVP is composed of SARS-CoV-2 Spike protein RBD delivered in a lipid-based nanoparticle vaccine platform (Park et al., 2020).

Link	Tested on	Impact factor	Notes	Publication date
Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2 Spike protein Animal model In vitro Mixed substance	BALB/c mice	7.73	The experimental vaccine elicited high and persistent anti-RBD (SARS-CoV-2 Spike protein) IgG response in mice.	Dec/20/2020